References for

Better Sex Through Chemistry

A Guide to the New Prosexual Drugs and Nutrients
By John Morgenthaler and Dan Joy

References

Introduction

	Gary P. What is love? Time. February 15th, 1993.
	Rosen RC; Ashton AK. Prosexual drugs: Empirical status of the `new aphrodisiacs.' Archives of Sexual Behavior. 22(6): p521-43, 1993.

Some Basic Physiology

	Buffum J. Pharmacosexology: The effects of drugs on sexual function, a review. J of Psychoactive Drugs. 14(1-2): p5-43, Jan-Jun, 1982.
	Dilman V; Dean, W. The Neuroendocrine Theory of Aging & Degenerative Disease. Pensacola, FL: The Center for Bio- Gerontology, 1992.
	Everitt, BJ; Fuxe K. Dopamine and sexual behavior in female rats. Effects of dopamine receptor agonists and sulpiride. Neurosci Lett (Netherlands) 4/3-4: p209-13, 1977.
	Mellow-Whipkit L. Drugs for sex: Real aphrodisiacs. Mondo 2000. Spring, 1991.
	Sodersten P; Hansen S; Eneroth P. Inhibition of sexual behavior in lactating rats. J Endocrinol. 99(2): p189-97, November 1983.
	Weizman R; Weizman A; Levi J; Gura V; Zevin D; Maoz B; Wijsenbeek H; Ben David M. Sexual dysfunction associated with hyper-prolactinemia in males and females undergoing hemodialysis. Psychosom Med. 45(3): p259-69, June 1983.

Part I: Natural Substances

Prosexual Nutrients

	Alexander JW; Gottschlich MM. Nutritional immunomodulation in burn patients. Crit Care Med. 18(2 suppl): p149-53, 1990.
	Anggard E. Nitric oxide: mediator, murderer, and medicine. The Lancet. 343: p1199-207, 1994.
	Associated Press. Researchers find male sex trigger. San Jose Mercury News. 2F: July 17, 1992.
	Burnett AL; Lowenstein CJ; Bredt DS; et al. Nitric oxide: a physiologic mediator of penile erection. Science. 257: p401-4, 1992.
	Clemens LG; Dohanich GP; Witcher JA. Cholinergic influences on estrogen-dependent seual behavior in female rats. J Comp Physiol Psychol. 95: p763-70, 1981.
	Clemens LG; Barr P; Dohanich GP. Cholinergic regulation of female sexual behavior in rats demonstrated by manipulation of endogenous acetylcholine. Physiol Behav. 45: p437-42, 1989.
	Daley JM; Reynolds J; Thom A; et al. Immune and metabolic effects of arginine in the surgical patient. Ann Surg. 208: p512-23, 1988.
	Drexler H; Zeiher AM; Meinzer K; Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet. 338: p1546-50, 1991.
	Freundlich N. Much ado about NO. Harvard Health Letter. 18: p6-8, 1993.
	Graham S. A Lecture to Young Men. Providence, Rhode Island: Weeden and Cory, 1834.
	Griffith RS; DeLong DC; Nelson JD. Relation of arginine-lysine antagonism to Herpes simplex growth in tissue. Chemotherapy. 27: p209-13, 1981.
	Hellstrom WJ; Monga M; Wang R; et al. Penile erection in the primate: induction with nitric-oxide donors. J Urol. 151: p1723-7, 1994.
	Hoffman M. A new role for gases: neurotransmission; the remarkable finding that nitric oxide carries nerve impulses initiates a novel concept of neurotransmission. Science. 252: p1788, 1991.
	Howe JW. Excessive Venery, Masturbation and Continence. New York: EB Treat, 1887.
	Keller DW; Polakoski KL. L-arginine stimulation of human sperm motility in vitro. Biol Reprod. 13: p154-7, 1975.
	Kellogg JH. Plain Facts for Old and Young: Embracing the Natural History and Hygiene of Organic Life. Burlington, Iowa: IF Stegner & Co, 1888.
	Knopf; Conn; Fajans; et al. Plasma growth hormone response to intravenous administration if amino acids. J Clin Endocrinol. 25: p1140-4, 1965.
	Kolata G. Key signals of cells found to be common gas. New York Times. C1, 2 July 1991.
	Mani SK; Allen JM; Rettori V; et al. Nitric oxide mediates sexual behavior in female rats. Proc Natl Acad Sci. 91: p6468-72, 1994.
	Merimee et al. Arginine-initiated release of human growth hormone. N Eng J Med 280: p1434-8, 1969.
	Palmer RMJ; Rees DD; Ashton DS; et al. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium dependent relaxation. Biochem Biophys Res Comm. 153: p1251-6, 1988.
	Papp G; Grof J; Molnar J; Jambor E. Die Rolle des Arginingehaltes und der Arginase-Aktivitat in der Fertilitat. Andrologia. 11: p37-41, 1979.
	Pau MY; Milner JA. Dietary arginine and sexual maturation of the female rat. J Nutr. 112: p1834-42, 1982.
	Pearson D; Shaw S. The Life Extension Weight Loss Program. New York: Doubleday & Co., 1986.
	Pearson D; Shaw S. The Life Extension Companion. New York: Warner Books, 1984.
	Pearson D; Shaw S. Life Extension: A Practical Scientific Approach. New York: Warner Books, 1982.
	Pearson D; Shaw S. Sexual effects of nutrients: arginine and choline. Lifenet News. II: p6, 1991.
	Ralli EP; Dunn SD. Relation of pantothenic acid to adrenal cortical function. Vit Horm. 11: p133-158, 1953.
	Rudman D; Axel MD; Hoskote S; et al. Effects of human growth hormone in men over 60 years old. N Engl J Med. 323: p1-5, 1990.
	Saito M; Broderick GA; Hypolite JA; Levin RM. Pharmacological effect of ethanol on the function of rabbit corporal cavernosal tissue. Pharmacology. 48: p335-40, 1994.
	Salvadorini F.; Todeschini G.; Tognetti G.; Marescotti V. Effects of oral treatment with arginine in subjects affected by hypospermia. Rass Int Clin Ter. 54: p319-30, 1974.
	Wang R; Domer FR; Sikka SC; et al. Nitric oxide mediates penile erection in cats. J Urol. 151: p234-7, 1994.
	Wilson HR; Harms RH. Evaluation of nutrient specifications for broiler breeders. Poult Sci. 63: p1400-6, 1984.
	Yallampalli C; Byam-Smith M; Nelson SO; Garfield RE. Steroid hormones modulate the production of nitric oxide and cGMP in the rat uterus. Endocrinology. 134: p1971-4, 1994.

GHB (gamma-hydroxybutyrate)

	Artru AA; Steen PA; Michenfelder JD.y-Hydroxybutyrate: Cerebral metabolic, vascular, and protective effects. Journal of Neurochemistry. 35(5): p1114-9, November 1980.
	Cash, CD. Gammahydroxybutyrate: An overview of the pros and cons for it being a neurotransmitter and/or a useful therapeutic agent. Neuroscience and Biobehavioral Reviews. 18(2): p291-304, 1994.
	Chin MY; Kreutzer RA; Dyer JE. Acute poisoning associated with gamma-hydroxybutyrate in California. West J Med (UNITED STATES). 156(4): p380-4, Apr 1992. (California Department of Health Services, Environmental Epidemiology and Toxicology Branch, Emeryville 94608.)
	Cooper, JR; Bloom, FE; Roth, RH. The biochemical basis of neuropharmacology, 2nd edition. New York, London, Toronto: Oxford University Press, 1974.
	Dean W; Morgenthaler J; Fowkes S. Smart Drugs II: The Next Generation. Petaluma, California: Smart Publications, 1993.
	Fadda F; Colombo G, Mosca E; Gessa GL. Suppression by gamma-hydroxybutyric acid of ethanol withdrawal syndrome in rats. Alcohol & Alcoholism. 24(5): p447-51, 1989. (Printed in Great Britain.)
	Fowkes, S. Q&A. Smart Drug News. 2(2): March 1993. (CERI, POB 4029, Menlo Park, CA, 94026-4029, tel:415-321-2374, fax:415-323-3864)
	Gallimberti L; Gentile N; Cibin M; Fadda F; Canton G; Ferri M; Ferrara SD; Gessa GL. Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome. The Lancet. p787-9, 30 September 1989.
	Kleimenova NN; Ostrovskaya RU; Arefolov VA. Effect of sodium hydroxybutyrate on the ultrastructure of the cross-striated muscle tissue myocytes during physical exercise. Byull Eksp Biol Med. 88(9): p358-61, 1979. (Inst Pharmacol, Moscow USSR.)
	Laborit H. Correlations between protein and serotonin synthesis during various activities of the central nervous system (slow and desynchronized sleep, learning and memory, sexual activity, morphine tolerance, aggressiveness, and pharmacological action of sodium gamma-hydroxybutyrate). Research Communications in Chemical Pathology and Pharmacology. 3(1): Jan 1972.
	Laborit H. Sodium 4-hydroxybutyrate. Int J Neuropharmacology. 3: p433-52, 1964. (Pergamon Press. Printed in Great Britain.)
	Ostrovskaya RU; Kleimenova NN; Kamisheva V; Molodavkin GM; Yavorskii AN; Boikko SS. Effect of sodium hydroxybutyrate on functional biochemical and morphological indexes of physical working ability. Farmakol Regul Protsessov Utomleniya (Moscow USSR). 39(56): p112-17, 1982.
	Pearson D; Shaw S. Life Extension: A Practical Scientific Approach. New York: Warner Books, 1982.
	Pearson D; Shaw S. Durk Pearson & Sandy Shaw's Life Extension Newsletter. 2: October 1988.
	Rogers P; Katel P. The new view from on high. Newsweek. 6 December 1993.
	Takahara J; Yunoki S; Yakushiji W; Yamauchi J; Yamane J; Ofuji T. Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans. J Clin Endocrinal Metab. 44: p1014, 1977.
	Vickers MD. Gammahydroxybutyric acid. Int Anaesthesia Clinic. 7: p75-89, 1969.
	Watson CM. Love Potions: A Guide to Aphrodisiacs and Sexual Pleasures. Tarcher/Perigee, 1993.

L-Dopa

	Angrist B; Gershon S. Clinical effects of amphetamine and L-dopa on sexuality and aggression. Comprehens psychiat (USA). 17(6): p715-22, 1976.
	Ballivet J; Marin A; Gisselmann A. [Aspects of the hypersexuality observed in the parkinsonian subject during treatment with levodopa.] Aspects de l'hypersexualite observee chez le parkinsonien lors du traitement par la L-dopa. Annmed-Psychol (France). 131(II/4): p515-22, 1973.
	Barbeau A. Neurological and psychiatric side effects of L-dopa. Pharmacol ther ser c (United Nations). 1(3-4): p475-94, 1976.
	Bianchine JR. Sexual function in Parkinson's disease. Med Aspects Hum Sex (USA). 13(4): p69-70, 1979.
	Block, W. Affects of bromocriptine on the brain. Life Extension Report. 13(10): p75-8, October 1993.
	Boyd et al. "Stimulation of human-growth-hormone secretion by L-dopa." New Engl J Med. 183(26): p1425-9, 1970.
	Brown E; Brown GM; Kofman O; Quarrington B. Sexual function and affect in parkinsonian men treated with L-dopa. Am J Psychiatry. 135(12): p1552-5, Dec 1978.
	Buffum J. Pharmacolsexology: The effects of drugs on sexual function, a review. J of Psychoactive Drugs. 14(1-2): p5-43, Jan-Jun, 1982.
	Castaigne P. [Levodopa and mental disturbances.] L-dopa et troubles psychiques. Int J Neurol (Montevideo) (Uruguay). 10(1-4): p178-85, 1975.
	Cotzias, GC; Miller, ST; Tang, LC; Papava siliou, PS; Wang, YY. "Levodopa, fertility and longevity." Science. 196: p549-551, 1977.
	Dean W; Morgenthaler J; Fowkes S. Smart Drugs II: The Next Generation. Petaluma, California: Smart Publications, 1993.
	Dilman V; Dean, W. The Neuroendochrine Theory of Aging & Degenerative Disease. Pensacola, FL: The Center for Bio-Gerontology, 1992.
	Fowkes, S. Q&A. Smart Drug News. 2(10): Feb 1994. (CERI, POB 4029, Menlo Park, CA, 94026-4029, tel:415-321-2374, fax:415-323-3864)
	Gawin FH. Drugs and eros: reflections on aphrodisiacs. J Psychoative Drugs. 10(3): p227-36, Jul-Sep 1979.
	Girke W; Xenakis Ch. [Side effects of L-dopa treatment.] Nebenwirkungen der L-dopa therapie. Dtsch Med Wschr (Germany, West).100(42): p2165-9, 1975.
	Gray GD; Davis HN; Dewsbury DA. Effects of L-dopa on the heterosexual copulatory behavior of male rats. Eur J Pharmacol (Amst) (Netherlands). 27(3): p367-70, 1974.
	Keyes DM; Janzik HH; Mayer K; et al. L-dopa effects on sexual behaviour: an experimental study. J Sex Res (USA). 12(2): p117-23, 1976.
	Koller WC; Veter-Overfield B; Williamson A; Busenbark K; Nash J; Parrish D. Sexual dysfunction in Parkinson's disease. Clin Neuropharmacol (USA). 13(5): p461-3, 1990.
	Laborit H. Correlations between protein and serotonin synthesis during various activities of the central nervous system (slow and desynchronized sleep, learning and memory, sexual activity, morphine tolerance, aggressiveness, and pharmacological action of sodium gamma-hydroxybutyrate). Research Communications in Chemical Pathology and Pharmacology. 3(1): Jan 1972.
	Malmnas CO. The significance of dopamine, versus other catecholamines, for L-dopa induced facilitation of sexual behavior in the castrated male rat. Pharm Biochem Behav (USA). 4(5): p521-6, 1976.
	Pearson D; Shaw S. Life Extension: A Practical Scientific Approach New York: Warner Books, 1982.
	Physicians' Desk Reference (PDR). Montvale, New Jersey: Medical Economics Data, a division of Medical Economics Company, Inc, 1994.
	Quinn NP; Toone B; Lang AE; et al. Dopa dose-dependent sexual deviation. Br J Psychiatry (England). 142(3): p296-8, 1983.
	Ryan EL; Frankel AI. The effect of L-3,4-dihydroxyphenylalanine (L-dopa) on the prolactin response to sexual behavior in the male rat. Neuroendocrinology (Switzerland). 28(5): p302-6, 1979.
	Selby G. Laevodopa in Parkinson's disease: an Australian trial. Neurology (Bombay) (India). 20(2 sup): p203-14, 1972.
	Sietnieks A; Meyerson BJ. Enhancement by progesterone of 5-hydroxytryptophan inhibition of the copulatory response in the female rat. Neuroendocrinology (Switzerland). 35(5): p321-6, 1982.
	Singer C; Weiner WJ; Sanchez-Ramos JR. Autonomic dysfunction in men with Parkinson's disease. Eur Neurol (Switzerland). 32(3): p134-40, 1992.
	Tagliamonte A; Fratta W; Del Fiacco M; Gessa GL. Possible stimulatory role of brain dopamine in the copulatory behavior of male rats. Pharm Biochem Behav (USA). 2(2): p257-60, 1974.
	Uitti RJ; Tanner CM; Rajput AH; Goetz CG; Klawans HL; Thiessen B. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol. 12(5): p375-83, Oct 1989.
	Vogel HP; Schiffter R. Hypersexuality--a complication of dopaminergic therapy in Parkinson's disease. Pharmacopsychiatria (Germany, West). 16(4): p107-10, Jul 1983.

Yohimbe & Yohimbine

	Adaikan PG; Ratnam SS. Pharmacology of penile erection in humans. Cardiovasc Intervent Radiol. 11(4): p191-4, 1988.
	Bowes MP; Peters RH; Kernan WJ Jr; Hopper DL. Effects of yohimbine and idazoxan on motor behaviors in male rats. Pharmacol Biochem Behav (USA),. 41(4): p(707-13, 1992.
	Buffum J. Pharmacosexology update) Yohimbine and sexual function. J Psychoact Drugs (USA). 17(2): p131-2, 1985.
	Buffum J. Pharmacolsexology: The Effects of Drugs on Sexual Function, a Review. J of Psychoactive Drugs. 14(1-2): p5-43, Jan-Jun, 1982.
	Clark JT. Suppression of copulatory behavior in male rats following central administration of clonidine. Neuropharmacology (United Kingdom). 30(4): p373-82, 1991.
	Clark JT; Smith ER; Davidson JM. Testosterone is not required for the enhancement of sexual motivation by yohimbine. Physiol Behav (USA). 35(4): p517-21, 1985.
	Clark JT; Smith ER; Davidson JM. Evidence for the modulation of sexual behavior by alpha-adrenoceptors in male rats. Neuroendocrinology (Switzerland). 41(1): p36-43, 1985.
	Clark JT; Smith ER; Davidson JM. Enhancement of sexual motivation in male rats by yohimbine. Science (United States). 225(4664): p847-9, Aug 24 1984.
	Costa R; Marino A. [On the eventual psychotropic, cardiovascular and aphrodisiac properties of yohimbine, an old drug with new indications.] Sulle eventuali proprieta psicotrope, cardioangioattive e afrodisiache della yoimbina, vecchio farmaco con nuove indicazioni. Clin Ter (Italy). 129(3): p159-68, May 15 1989.
	Davis GA; Kohl R. The Influence of alpha receptors on lordosis in the female rat. Pharm Biochem Behav (USA). 6(1): p47-53, 1977.
	Deamer RL; Thompson JF. The role of medications in geriatric sexual function. Clin Geriatr Med (USA). 7(1): p95-111, 1991.
	Dohler DD; Jarzab B; Sickmoller PM; Kokocinska D; Kaminski M; Gubala E; Achtelik W; Wagiel J. Influence of neurotransmitters on sexual differentiation of brain structure and function. Exp Clin Endocrinol (Germany). 98(2): p99-109, 1991.
	Friesen K; Palatnik W; Tenenbein M. Benign course after massive ingestion of yohimbine. J Emerg Med (United States). 11(3): p287-8, May-Jun 1993.
	Gawin FH. Drugs and eros: Reflections on aphrodisiacs. J Psychoative Drugs. 10(3): p227-36, Jul-Sep 1979.
	Gottlieb A. Sex Drugs and Aphrodisiacs. 20th Century Alchemist, 1974.
	Green J. The Male Herbal: Health Care for Men and Boys. Freedom, California: Crossing Press, 1991.
	Griffin GM. Aphrodisiacs For Men. Added Dimensions Publishing, 1991.
	Grossman E; Rosenthal T; Peleg E; Holmes C; Goldstein DS. Oral yohimbine increases blood pressure and sympathetic nervous outflow in hypertenseive patients. Cardiovasc Pharmacol (United States). 22(1): p22-6, Jul 1993.
	Hollander E; McCarley A. Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers. J Clin Psychiatry (United States). 53(6): p207-9, Jun 1992.
	Jacobsen FM. Fluexotine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry (United States). 53(4): p119-22, Apr 1992.
	Laborit H. Correlations Between Protein and Serotonin Synthesis During Various Activities of the Central Nervous System (Slow and Desynchronized Sleep, Learning and Memory, Sexual Activity, Morphine Tolerance, Aggressiveness, and Pharmacological Action of Sodium Gamma-Hydroxybutyrate). Research Communications in Chemical Pathology and Pharmacology. 3(1): Jan 1972.
	Lin SN; Yu PC; Yang MC; Chang LS; Chiang BN; Kuo JS. Local suppressive effect of clonidine on penile erection in the dog. J Urol (United States). 139(4): p849-52, Apr 1988.
	Morales A; Condra M; Owen JA; Surridge DH; Fenemore J; Harris C. Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial. J Urol (United States). 137(6): p1168-72, Jun 1987.
	Morpurgo B; Rozenboim I; Robinzon B. Effect of yohimbine on the reproductive behavior of the male Nile crocodile Crocodylus nilicotus. Pharmacol Biochem Behav (USA). 43(2): p449-52, 1992.
	Naumenko EV; Amstislavskaja TG; Osadchuk AV. The role of adrenoceptors in the activation of the hypothalamic-pituitary-testicular complex of mice induced by the presence of a female. USSR Exp Clin Endocrinol (Germany). 97(1): p1-11, 1991.
	Physicians' Desk Reference (PDR). Montvale, New Jersey: Medical Economics Data, a division of Medical Economics Company, Inc., 1994.
	Price J; Grunhaus LJ. Treatment of Clomipramine-induced anorgasmia with yohimbine: A case report. J Clin Psychiatry (USA). 51(1): p32-3, 1990.
	Reid K; Surridge DH; Morales A; Condra M; Harris C; Owen J; Fenemore J. Double-blind trial of yohimbine in treatment of psychogenic impotence. Lancet (England). 2(8556): p241-3, 22 Aug 1987.
	Richard Alan Miller. The Magical and Ritual Use of Aphrodisiacs. Destiny Books, 1985.
	Rosen RC; Ashton AK. Prosexual Drugs: Empirical status of the `new aphrodisiacs.' Archives of Sexual Behavior. 22(6): p521-43, 1993.
	Sala M; Braida D; Leone MP; Calcaterra P; Monti S; Gori E. Central effect of yohimbine on sexual behavior in the rat. Physiol Behav (USA). 47(1): p165-73, 1990.
	Smith ER; Davidson JM. Yohimbine attenuates aging-induced sexual deficiencies in male rats. Physiol Behav (USA). 47(4): p631-634, 1990.
	Smith ER; Lee RL Schnur SL; Davidson JM. Alpha2-adrenoceptor antagonists and male sexual behavior: I Mating Behavior Physiol Behav (USA). 41(1): p7-14, 1987A.
	Smith ER; Lee RL Schnur SL; Davidson JM. Alpha2-adrenoceptor antagonists and male sexual behavior: II Erectile and ejaculatory reflexes. Physiol Behav (USA). 41(1): p15-9, 1987B.
	Sonda LP; Mazo R; Chancellor MB. The role of yohimbine in the treatment of erectile impotence. J Sex Marital Ther (United States). 16(1): p15-21, Spring 1990.
	Stafford, Peter. Psychedelics Encyclopedia, 3rd Edition. Ronin Press, 1993.
	Susset JG; Tessier CD; Wincze J; Bansal S; Malhotra C; Schwacha MG. Effect of yohimbine hydrochloride on erectile impotence: a double-blind study. J Urol (United States). 141(6): p1360-3, Jun 1989.
	Watson CM. Love Potions: A Guide to Aphrodisiacs and Sexual Pleasures. Tarcher/Perigee, 1993.
	Yates A; Wolman W. Aphrodisiacs: Myth and Reality. Medical Aspects of Human Sexuality. p58-61, December 1991.
	Yonezawa A; Kawamura S; Ando R; Tadano T; Kisara K; Kimura Y. Chronic clonidine treatment and its termination: Effects on penile erection and ejaculation in the dog. Life Sci. (USA). 51(25): p1999-2007, 1992.

Part II: Synthetic Substances

Bromocriptine

	Andronova LM. [Possibilities for behavior correction in a learned ethanol preference in female and male white rats.] Farmakol Toksikol. 50(4): p55-60, Jul-Aug 1987.
	Ayalon D; Eckstein N; Homonnai ZT; Paz GF; Eshel A; Reider. Effects of long-term treatment with bromocriptine on pituitary prolactinoma in a male. I Int J Gynaecol Obstet. 20(6): p481-5, Dec 1982.
	Baas H.; Schneider E.; Fischer P.-A.; Japp G. Mesulergine and bromocriptine in long-term treatment of advanced parkinsonism. West J Neural Transm. (Austria). 64(1): p45-54, 1985.
	Bacz A.; Klimek R. Clinical evaluation of short-lasting administration of bromcriptine preparation in men. Klin Endokrynol. 50(10): p875-8, 1979.
	Barnett PS; Palazidou E; Miell JP; Coskeran PB; Butler J; Dawson JM; Maccabe J; McGregor AM. Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502. Q J Med 81(295): p891-906, Nov 1991.
	Bergh T.; Nillius J.; Wide L. Bromocriptine treatment of 42 hyperprolactinaemic women with secondary amenorrhoea. Sweden Acta Endocrinol. (Copenhagen) (Denmark). 88(3): p435-51, 1978.
	Besser GM; Wass JA; Thorner MO. Acromegaly--results of long term treatment with bromocriptine. Acta Endocrinol Suppl (Copenh). 216: p187-98, 1978.
	Blin O.; Schwertschlag U.S.; Serratrice G. Painful clitorial tumescence during bromocriptine therapy (25). Lancet (United Kingdom). 337(8751): p1231-2, 1991.
	Block, W. Affects of Bromocriptine on the Brain. Life Extension Report. 13(10): p75-8, October 1993.
	Bommer, J; Ritz E; del Pozo E; Bommer G. Improved sexual function in male haemodialysis patients on bromocriptine. Lancet. 2(8141): p496-7, 8 Sep 1979.
	Brown E; Brown GM; Kofman O; Quarrington B Am J. Sexual function and affect in parkinsonian men treated with L-dopa. Psychiatry. 135(12): p1552-5, Dec 1978.
	Buffum J. Pharmacolsexology: The Effects of Drugs on Sexual Function, a Review. J of Psychoactive Drugs. 14(1-2): p5-43, Jan-Jun, 1982.
	Buvat J; Lemaire A; Buvat-Herbaut M; Fourlinnie JC; Racadot A; Fossati P. Hyperprolactinemia and sexual function in men. Horm Res. 22(3): p196-203, 1985.
	Ciccarelli E; Miola C; Grottoli S; Avataneo T; Lancranjan I; Camanni F. Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine. J Clin Endocrinol Metab (US). 76(2): p484-8, Feb 1993.
	Cincotta AH; Meier AH. Reductions of body fat stores and total plasma cholesterol and triglyceride concentrations in several species by bromocriptine treatment. Life Sciences 45: p2247-54, 1989.
	Clinical Research, Sandoz Limited, Basle Switzerland. The safety of bromocriptine in long-term use: A review of the literature. Curr Med Res Opin. (UK). 10(1): p25-51, 1986.
	Cocores JA; Dackis CA; Gold MS. Sexual dysfunction secondary to cocaine abuse in two patients. J Clin Psychiatry. 47(7): p384-5, Jul 1986.
	Dallo J; Lekka N; Knoll J. The ejaculatory behavior of sexually sluggish male rats treated with (-)deprenyl, apomorphine, bromocriptine and amphetamine. Pol J Pharmacol Pharm. 38(3): p251-5, May-Jun 1986.
	Deamer RL; Thompson JF. The role of medications in geriatric sexual function. University of California, Los Angeles School of Medicine. Clin Geriatr Med. 7(1): p95-111, Feb 1991.
	Dean W; Morgenthaler J; Fowkes S. Smart Drugs II: The Next Generation. Petaluma, California: Smart Publications, 1993.
	Dilman V; Dean, W. The Neuroendochrine Theory of Aging & Degenerative Disease. Pensacola, FL: The Center for Bio- Gerontology, 1992.
	el-Beheiry A; Souka A; el-Kamshoushi A; Hussein S; el-Sabah K. Hyperprolactinemia and impotence. Arch Androl. 21(3): p211-4, 1988.
	Ermolenko VM; Kukhtevich AV; Dedov II; Bunatian AF; Melnichenko GA; Gitel EP. Parlodel treatment of uremic hypogonadism in men. Nephron. 42(1): p19-22, 1986.
	Everitt BJ. Monoamines and sexual behaviour in non-human primates. Ciba Found Symp. (62): p329-58, Mar 14-16 1978.
	Eversmann T; Eichinger R; Fahlbusch R; Rjosk HK; von Werder K. [Hyperprolactinemia in the male: clinical aspects and therapy.] Schweiz Med Wochenschr. 111(47): p1782-9, 21 Nov 1981.
	Foster R.S.; Mulcahy J.J.; Callaghan J.T.; Crabtree R.; Brashear D. Role of serum prolactin determination in evaluation of impotent patient. Urology (USA). 36(6): p499-501, 1990.
	Grimes JD; Hassan MN. Bromocriptine in the long-term management of advanced Parkinson's disease. Can J Neurol Sci (Canada). 10(2): p86-90, 1983.
	Huang et al, "Induction of estrous cycles in old non-cyclic rats by progesterone, ACTH, ether stree, or L-dopa." Neuroendocrin. 20: p21-34, 1976.
	Julien, R. A Primer of Drug Action, 5th Edition. New York: W. H. Freeman and Company, 1988.
	Kaliszuk S; Borzecki Z; Swies Z. The influence of bromocriptine on sexual activity in ethanol-exposed male rats. Sklodowska [Med] (Poland).44: p109-14, 1989.
	Katzir D; Rosenberg T; Ramot Y; Gaver-Shavit A; Gilboa Y. [Treatment of prolactin-secreting pituitary tumors with bromocriptine.] Harefuah. 118(3): p141-5, Feb 1, 1990.
	Kirby RW; Kotchen TA; Rees ED. Hyperprolactinemia--a review of recent clinical advances. Arch Intern Med. 139(12): p1415-9, Dec 1979.
	Kocijancic A; Prezelj J; Vrhovec I; Lancranjan I. Parlodel LAR in the treatment of macroprolactinomas. Acta Endocrinol (Copenh). 122(2): p272-6, Feb 1990.
	Koenig MP; Zuppinger K; Liechti B. Hyperprolactinemia as a cause of delayed puberty: successful treatment with bromocriptine. J Clin Endocrinol Metab. 45(4): p825-8, Oct 1977.
	Konig MP; Kopp P. [Hyperprolactinemia.] Schweiz Med Wochenschr. 116(9): p265-70, Mar 1 1986.
	Koppelman MC; Parry BL; Hamilton JA; Alagna SW; Loriaux DL. Effect of bromocriptine on affect and libido in hyperprolactinemia. Am J Psychiatry. 144(8): p1037-41, Aug 1987.
	Lamberts SW; Quik RF. A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia. J Clin Endocrinol Metab. 72(3): p635-41, Mar 1991.
	Landolt AM; Froesch ER. [Prolactin producing hypophyseal adenoma: diagnosis and therapeutic possibilities.] Schweiz Med Wochenschr. 115(23): p803-9, 8 Jun 1985.
	Martin-Du Pan R. [Neuroleptics and sexual dysfunction in man. Neuroendocrine aspects] Schweiz Arch Neurol Neurochir Psychiatr. 122(2): p285-313, 1978.
	Mbanya J.-C.N.; Mendelow A.D.; Crawford P.J.; Hall K.; Dewar J.H.; Kendall-Taylor P. Rapid resolution of visual abnormalities with medical therapy alone in patients with large prolactinomas. J Neurosurg. (United Kingdom). 7(5:): p519-527, 1993.
	Montini M; Pagani G; Gianola D; Pagani MD; Salmoiraghi M; Ferrari L; Lancranjan I. Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine. J Clin Endocrinol Metab. 63(1): p266-8, Jul 1986.
	Moussa, 1985 MA; Bayoumi A; Al-Khars A; Thulesius O. Adverse drug reaction monitoring in Kuwait (1981-1984). J Clin Pharmacol. 25(3): p176-81, Apr 1985.
	Muir JW; Besser GM; Edwards CR; Rees LH; Cattell WR; Ackrill P; Baker LR. Bromocriptine improves reduced libido and potency in men receiving maintenance hemodialysis. Clin Nephrol. 20(6): p308-14, Dec 1983.
	Nagulesparen M; Ang V; Jenkins JS. Bromocriptine treatment of males with pituitary tumours, hyperprolactinaemia, and hypogonadism. Clin Endocrinol (Oxf). 9(1): p73-9, Jul 1978.
	Okkens AC; van Haaften B; Nickel R. [Fertility problems in the bitch.] Vakgroep Geneeskunde van Gezelschapsdieren, Utrecht. Tijdschr Diergeneeskd. 117(8): p229-34, Apr 15 1992.
	Pearson D; Shaw S. Life Extension: A Practical Scientific Approach. New York: Warner Books, 1982.
	Physicians' Desk Reference (PDR). Montvale, New Jersey: Medical Economics Data, a division of Medical Economics Company, Inc., 1994.
	Perret M; Schilling A. Role of prolactin in a pheromone-like sexual inhibition in the male lesser mouse lemur. J Endocrinol. 114(2): p279-87, Aug 1987.
	Pierini A.A.; Nusimovich B. Male diabetic sexual impotence: Effects of dopaminergic agents. Argentina Arch Androl. (USA). 6(4): p347-50, 1981.
	Rigaud P; Jacquet G; Viennet G; Bittard H. [A rare psychogenic anejaculation. Report of a case of prolactin adenoma.] Une etrange anejaculation psychogene. A propos d'un cas d'adenome a prolactine. Prog Urol (France). 2(3): p459-63, June 1992.
	Schwartz MF; Bauman JE; Masters WH. Hyperprolactinemia and sexual disorders in men. Biol Psychiatry. 17(8): p861-76, Aug 1982.
	Sobrinho L.G.; Nunes M.C.; Calhaz-Jorge C.; et al. Effect of treatment with bromocriptine on the size and activity of prolactin producing pituitary tumours. Acta Endocrinol. 96(1): p24-9, 1981.
	Sodersten P; Hansen S; Eneroth P. Inhibition of sexual behaviour in lactating rats. J Endocrinol. 99(2): p189-97, Nov 1983.
	Sodersten P; Eneroth P J. Effects of exposure to pups on maternal behaviour, sexual behaviour and serum prolactin concentrations in male rats. Endocrinol. 102(1): p115-9, Jul 1984.
	Staub J.J.; Althaus B.; Wiggli U.; Gratzl O. Drug treatment of hyperprolactinemia and acromegaly. Schweiz Med Wochenschr (Switzerland). 113(20): p733-8, 1983.
	Stegmayr B; Skogstrom K. Hyperprolactinaemia and testosterone production. Observations in 2 men on long-term dialysis. Horm Res. 21(4): p224-8, 1985.
	Sullivan G; Lukoff D. Sexual side effects of antipsychotic medication: evaluation and interventions. Hosp Community Psychiatry. 41(11): p1238-41, Nov 1990.
	Toyokura Y.; Mizuno Y.; Kase M.; et al. Effects of bromocriptine on Parkinsonism. A nation-wide collaborative double-blind study. J Pn Acta Neurol Scand (DE). 72(2): p157-70, 1985.
	Tsakok FH; Yong YM; Ng CS. The use of bromocriptine in hyperprolactinemia and galactorrhea in Singapore. Int J Gynaecol Obstet. 23(2): p109-13, Apr 1985.
	Uitti RJ; Tanner CM; Rajput AH; Goetz CG; Klawans HL; Thiessen. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol. 12(5): p375-83, Oct 1989.
	Van Loon GR. New drugs in the treatment of pituitary disorders. Prim Care. 4(4): p721-37, Dec 1977.
	Vircburger MI; Prelevic GM; Peric LA; Knezevic J; Djukanovic L J. Testosterone levels after bromocriptine treatment in patients undergoing long-term hemodialysis. Androl. 6(2): p113-6, Mar-Apr 1985.
	Waddell TG; Ibach DM. Modern chemical aphrodisiacs. USA Indian J Pharm Sci (India). 51(3): p79-82, 1989.
	Wass J.A.H.; Thorner M.O.; Morris D.V.; et al. Long term treatment of acromegaly with bromocriptine. Brit Med J (England). 1(6065): p875-8, 1977.
	Weizman R; Weizman A; Levi J; Gura V; Zevin D; Maoz B; Wijsenbeek H; Ben David M. Sexual dysfunction associated with hyperprolactinemia in males and females undergoing hemodialysis. Psychosom Med. 45(3): p259-69, Jun 1983.
	Werder Kv; Fahlbusch R; Landgraf R; Pickardt CR; Rjosk HK; Scriba PC. Treatment of patients with prolactinomas. J Endocrinol Invest. 1(1): p47-58, Jan 1978.
	Werner S; Hall K; Sjoberg HE. Bromocriptine therapy in patients with acromegaly: effects on growth hormone, somatomedin A and prolactin. Acta Endocrinol Suppl (Copenh). 216: p199-206, 1978.
	Winters SJ; Troen P. Altered pulsatile secretion of luteinizing hormone in hypogonadal men with hyperprolactinaemia. Clin Endocrinol (Oxf). 21(3): p257-63, Sep 1984.

Deprenyl

	Block, W. Affects of Bromocriptine on the Brain. Life Extension Report. 13(10): p75-8, October 1993.
	Dean W; Morgenthaler J; Fowkes S. Smart Drugs II: The Next Generation. Petaluma, California: Smart Publications, 1993.
	Dilman V; Dean, W. The Neuroendochrine Theory of Aging & Degenerative Disease. Pensacola, FL: The Center for Bio- Gerontology, 1992.
	Dallo J; Lekka N; Knoll J. The ejaculatory behavior of sexually sluggish male rats treated with (-)deprenyl, apomorphine, bromocriptine and amphetamine Pol J Pharmacol Pharm Poland. 38(3): p251-5, 1986.
	Dallo J; Yen TT; Knoll J. The aphrodisiac effect of (-)deprenyl in male rats. Acta Physiol Hung (Hungary). 75 Suppl: p75-6, 1990.
	Dallo J.; Knoll J. Effect of (-)-para-fluoro-deprenyl on survival and copulation in male rats. Acta Physiol Hung (Hungary).79(2): p125-9, 1992.
	Fowkes, S. Deprenyl: The Anti-Aging Drug. Smart Drug News. 2(5): Oct 1993. (CERI, POB 4029, Menlo Park, CA, 94026- 4029, tel:415-321-2374, fax:415-323-3864)
	Fowkes, S. Q&A. Smart Drug News. 2(10): Feb 1994. (CERI, POB 4029, Menlo Park, CA, 94026-4029, tel:415-321-2374, fax:415-323-3864)
	Knoll J. Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand Suppl (Denmark). 95: p57-80, 1983(A).
	Knoll J. (-)Deprenyl-medication: A strategy to modulate the age-related decline of the striatal dopaminergic system. J Am Geriatr Soc (USA). 40(8): p839-847, 1992.
	Knoll J. [Medical strategy for improving the quality of life in senescence]. Medikamentose Strategie zur Verbesserung der Lebensqualitat in der Seneszenz. Wien Med Wochenschr Suppl (Austria). 98: p1-18, 1986.
	Knoll J. The facilitation of dopaminergic activity in the aged brain by (-)deprenyl. A proposal for a strategy to improve the quality of life in senescence. Mech Ageing Dev (Switzerland). 30(2): p109-22, May 13 1985.
	Knoll J; Yen TT; Dallo J. Long-lasting, true aphrodisiac effect of (-)-deprenyl in sexually sluggish old male rats. Mod Probl Pharmacopsychiatry (Switzerland). 19: p135-53, 1983(B).
	Knoll J; Dallo J; Yen TT. Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (-)deprenyl. Life Sci (USA). 45(6): p525-31, 1989.
	Pearson D; Shaw S. Durk Pearson & Sandy Shaw's Life Extension Newsletter. No 2, October 1988.
	Physicians' Desk Reference (PDR). Montvale, New Jersey: Medical Economics Data, a division of Medical Economics Company, Inc., 1994.
	Rosen RC; Ashton AK. Prosexual Drugs: Empirical status of the `new aphrodisiacs.' Archives of Sexual Behavior. 22(6): p521-43, 1993.
	Schatzberg AF; Cole JO. Manual of Clinical Psychopharmacology, 2nd Edition. Washington, DC, London, England: American Psychiatric Press Inc. 1990.
	Stoessl AJ. Prevention and management of late stage complications in Parkinson's disease. Can J Neurol Sci (Canada).19(1 SUPPL): p113-6, 1992.
	Tran Ty Yen; Dallo J; Knoll J. Aphrodisiac action of selective monoamine oxidase inhibitors in male rats. Kiserl Orvostud (Hungary). 33(5): p483-87, 1981.
	Yates A; Wolman W. Aphrodisiacs: Myth and Reality: Medical Aspects of Human Sexuality. p58-65, Dec 1991.
	Yen TT; Dallo J; Knoll J. The aphrodisiac effect of low doses of (-) deprenyl in male rats. Pol J Pharmacol Pharm (Poland). 34(5-6): p303-8, Nov-Dec 1982.